3 Drug Pricing Strategy Considerations Under Biden Admin.

By Margaux Hall (February 12, 2021, 5:31 PM EST) -- The Biden administration stands at a critical crossroads as it rolls out its agenda for pharmaceutical innovation, on the one hand, and addressing drug pricing, on the other hand.

The COVID-19 pandemic has demonstrated the importance and the urgency of many types of biopharmaceutical innovation. And, by all accounts, the drugs and biologics launched during the next four years — not to mention the next decade — will be groundbreaking and will hold great promise to transform patient lives.

Foundational scientific discoveries[1] have changed the way we understand cancers, immunological conditions and other diseases, and are already transforming clinical practice....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!